Abstracts tagged "Adalimumab"

Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson¹, Sarika Ogale², Fred Dejonckheere³ and Sean Sullivan⁴, ¹Pharmacy, University of Washington, Seattle, WA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…
Abstract Number: 1140 • 2012 ACR/ARHP Annual Meeting
Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
Vanesa Calvo-Río¹, Ricardo Blanco², Manuel Díaz-Llopis³, David Salom⁴, Carmen García-Vicuña⁵, Miguel Cordero-Coma⁶, Norberto Ortego⁷, Marta Suarez-de-Figueroa⁸, J. Carlos Fernandez-Cid⁹, A. Fonollosa Calduch¹⁰, Ángel M. García-Aparicio¹¹, Jose M. Benítez-del-Castillo¹², Jose L. Olea¹³, Javier Loricera¹⁴ and Miguel Angel González-Gay¹⁵, ¹Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Universitario La Fe de Valencia, Valencia, ⁴Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ⁵Hospital Sant Joan de Déu, Barcelona, Barcelona, ⁶Departament of Ophthalmology, Hospital de León, León, Spain, ⁷Hospital San Cecilio. Granada, Granada, Spain, ⁸Department of Ophthalmology, Hospital Ramon y Cajal, Madrid, Spain, ⁹Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ¹⁰Ophthalmology, Hospital de Cruces, Barakaldo, Spain, ¹¹Hospital Virgen Salud, Toledo, Toledo, ¹²Departament of Ophthalmology, Hospital Clínico San Carlos, Madrid, ¹³Departament of Ophthalmology, Hospital Son Dureta, Palma de Mallorca, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ¹⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain
Background/Purpose: To assess the efficacy and safety of treatment with adalimumab therapy in patients with refractory Juvenile Idiopathic Arthritis (JIA)-associated uveitis. Methods: Multicenter study on…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 1015 • 2012 ACR/ARHP Annual Meeting
Analysis of Integrated Radiographic Data for Two Long-Term, Open-Label Extension Studies of Adalimumab
Désirée van der Heijde¹, Robert Landewé², Edward Keystone³, Ferdinand C. Breedveld⁴, Shufang Liu⁵ and Neelufar Mozaffarian⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ³University of Toronto, Professor of Medicine, Toronto, ON, Canada, ⁴Dept of Rheumatology C1R, Leiden University Medical Center, Leiden, Netherlands, ⁵Immunology Development, Abbott, Abbott Park, IL, ⁶Abbott, Abbott Park, IL
Background/Purpose: The assessment of radiographic data from long-term studies in patients (pts) with rheumatoid arthritis (RA) poses a significant challenge, given the potential involvement of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].